Dermatology

What does a strong physician-patient connection look like in 2020?

A comparative assessment shows children with psoriasis have a four-fold increased risk of reaching PASI 75 with biologics.

The oral treatment becomes the first of its kind indicated for the reduction of food allergic reaction risks and severity in the US.

The FDA will rule on the type 2 inflammation-targeting biologic for another indication this May.

New findings show a greater risk of longer, more persistent cases of atopic dermatitis among children with mothers suffering from depression.

A certified physician assistant breaks down how dermatology specialty demand has influenced the modern care team.

The new topical lotion is aimed at treating patients at least 9 years old with acne vulgaris.

A look back at how chronic disease management, physician shortage, and newer therapies shaped the modern care team.

How primary care fits into the scheme of patient management, and what new therapies may mean for atopic dermatitis.

Nearly one dozen therapies have reached the psoriasis market, and the new standard is at least 90% skin clearance—an achievement previously unmet.

Though research behind preventive measures is lacking, there are common steps that could be taken to reduce pediatric risk.

Assessing a food allergy patient's overall diet during immunotherapy trials could unlock understanding how the microbiome affects the allergic reaction.

New findings show Viaskin Peanut provided significant improvements to HRQL over placebo in a pair of its clinical trials.

Distinguishing biologic-eligible patients may still need further biomarker and disease severity research.

How the annual college meeting has come to address the rapidly developing field of immunotherapy.

The pivotal phase 3 findings are the largest to assess a systemic pediatric atopic dermatitis treatment, to date.

After decades of development, researchers are nearing clinical trials for immune response-shifting vaccines. Will they be feasible for patients, and accepted by clinicians?

A new study presented at CHEST 2019 shows pulmonologists and ILD specialists will either reduce or temporarily interrupt antifibrotic care, depending on the form of adverse events a patient is experiencing.